| Name | Title | Contact Details |
|---|---|---|
Michael Moynihan |
VP Research & Development | Profile |
Vyripharm® is a disruptive biopharmaceutical innovator in personalized medicine. We are challenging the status quo by shifting medical paradigms through the integration of traditional and alternative medicines. Our purpose is to push the boundaries to drive innovation by turning groundbreaking science into cutting edge diagnostics and therapeutics.
Sapphire Biotech, Inc.`s diagnostic tool is being used to study the company`s enzyme biomarker to detect pancreatic cancer earlier than circulating tumor cells.
Centre for Commercialization of Regenerative Medicine , a Canadian not-for-profit organization funded by the Government of Canada`s Networks of Centres of Excellence program, the Province of Ontario, and leading academic and industry partners, supports the development of regenerative medicines and associated enabling technologies, with a specific focus on cell and gene therapy. CCRM aims to accelerate the translation of scientific discovery into marketable products for patients with specialized teams funding, and infrastructure. CCRM sources and evaluates intellectual property from around the globe, offers various consulting services, conducts development projects with partners, and establishes new companies built around strategic bundles of intellectual property. CCRM is the commercialization partner of the Ontario Institute for Regenerative Medicine and the University of Toronto`s Medicine by Design. CCRM is hosted by the University of Toronto and was launched in Toronto`s Discovery District on June 14, 2011.
DEKA Research and Development Corporation is a Manchester, NH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Pars Environmental is a Trenton, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.